

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 0656)

CONTINUING CONNECTED TRANSACTIONS

SUPPLY OF PHARMACEUTICAL PRODUCTS BY SHANGHAI TRANSFUSION TO SHANGHAI BLOOD CENTRE

Shanghai Transfusion entered into the 2008 Pharmaceutical Products Sales Agreement dated 12 August 2008 with Shanghai Blood Centre for a term of one year, namely, for the period from 12 August 2008 to 11 August 2009, which was extended to 31 December 2009 by a supplemental agreement dated 10 March 2009 and entered into by the parties. It was originally expected by the Company that the continuing connected transaction under the 2008 Pharmaceutical Products Sales Agreement was exempted from reporting, announcement and independent shareholders' approval requirements on the basis that all the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) calculated using the original estimates would be less than 0.1% for the year ended 31 December 2008.

The Directors became aware in early March 2009 in the course of the annual review of the historical connected transactions and continuing connected transactions of the Group that the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) calculated by reference to the financial information from the management accounts of the Company for the year ended 31 December 2008 exceeded 0.1% but were less than 2.5%. The Company must therefore comply with the applicable provisions of Chapter 14A of the Listing Rules in relation to such transaction.

Shanghai Transfusion is a subsidiary of the Company. Shanghai Blood Centre is a substantial shareholder of Shanghai Transfusion and is therefore a connected person of the Company, and the transaction under the 2008 Pharmaceutical Products Sales Agreement constitutes a continuing connected transaction of the Company under Chapter 14A of the Listing Rules.

As each of the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) in respect of the annual cap for the year ending 31 December 2009 is more than 0.1% but less than 2.5%, the transaction under the 2008 Pharmaceutical Products Sales Agreement for the year ending 31 December 2009 is only subject to the reporting and announcement requirements under Rules 14A.45 to 14A.47 of the Listing Rules, and is exempt from the independent shareholders' approval requirement under Rule 14A.48 of the Listing Rules.

INTRODUCTION

As disclosed in the section headed "Business - Connected Transactions" of the Prospectus, Shanghai Transfusion, a subsidiary of the Company, entered into the 2006 Pharmaceutical Products Sales Agreement dated 22 August 2006 with Shanghai Blood Centre for a term of one year, namely, for the period from 22 August 2006 to 21 August 2007, whereby, Shanghai Transfusion had agreed to supply certain pharmaceutical products to Shanghai Blood Centre upon its request from time to time during the term thereof. Shanghai Transfusion continued to supply pharmaceutical products to Shanghai Blood Centre upon its request from time to time after the expiry of the term of the 2006 Pharmaceutical Products Sales Agreement without any written agreement for the period from 22 August 2007 to 11 August 2008.

The applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) of the continuing connected transaction in respect of the supply of pharmaceutical products to Shanghai Blood Centre by Shanghai Transfusion were less than 0.1% for the year ended 31 December 2007, and thus, such continuing connected transaction was exempted from reporting, announcement and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

Shanghai Transfusion entered into the 2008 Pharmaceutical Products Sales Agreement dated 12 August 2008 with Shanghai Blood Centre for a term of one year, namely, for the period from 12 August 2008 to 11 August 2009, which was extended to 31 December 2009 by a supplemental agreement dated 10 March 2009 and entered into by the parties. It was originally expected by the Company that the continuing connected transaction under the 2008 Pharmaceutical Products Sales Agreement was exempted from reporting, announcement and independent shareholders' approval requirements on the basis that all the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) calculated using the original estimates would be less than 0.1% for the year ended 31 December 2008.

The Directors became aware in early March 2009 in the course of the annual review of the historical connected transactions and continuing connected transactions of the Group that the

applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) calculated by reference to the financial information from the management accounts of the Company for the year ended 31 December 2008 exceeded 0.1% but were less than 2.5%. The Company must therefore comply with the applicable provisions of Chapter 14A of the Listing Rules in relation to such transaction.

2008 PHARMACEUTICAL PRODUCTS SALES AGREEMENT

Background

Shanghai Transfusion entered into the 2008 Pharmaceutical Products Sales Agreement with Shanghai Blood Centre, whereby, Shanghai Transfusion has agreed to supply certain pharmaceutical products to Shanghai Blood Centre upon its request from time to time, which constitutes a continuing connected transaction of the Company under Chapter 14A of the Listing Rules.

Date

12 August 2008

Parties

- (i) Shanghai Transfusion
- (ii) Shanghai Blood Centre

Continuing Transaction

Pursuant to the 2008 Pharmaceutical Products Sales Agreement, Shanghai Transfusion has agreed to supply certain pharmaceutical products to Shanghai Blood Centre upon its request from time to time.

Term and Termination

The 2008 Pharmaceutical Products Sales Agreement is for a term of one year commencing from 12 August 2008 and ending on 11 August 2009, which was extended to 31 December 2009 by a supplemental agreement dated 10 March 2009 and entered into by the parties. Upon expiry, the 2008 Pharmaceutical Products Sales Agreement will, subject to compliance with the requirements of the Listing Rules, be renewed for a further period of one year.

Price Determination

Under the 2008 Pharmaceutical Products Sales Agreement, the parties have agreed the price per unit of the pharmaceutical products, which were determined by reference to the relevant market prices.

Transaction Volume

Due to the rapid diminishment of the market capitalisation of the Company in the year of 2008, the Company has not estimated with sufficient accuracy the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) of the continuing connected transaction under the 2008 Pharmaceutical Products Sales Agreement for the year ended 31 December 2008. The Company had not therefore published an announcement at the time when the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) of the transaction volume of the 2008 Pharmaceutical Products Sales Agreement had exceeded 0.1% for the year ended 31 December 2008, in compliance with the requirements under Rule 14A.47 of the Listing Rules.

The actual value of transaction for the three years ended 31 December 2006, 2007 and 2008 (by reference to the financial information from the management accounts of the Company for the year ended 31 December 2008), respectively, were as follows:

Historical Transaction Volume

Transaction	Year ended 31 December 2006 (RMB) Actual value	Year ended 31 December 2007 (RMB) Actual value	Year ended 31 December 2008 (RMB) Actual value
Supply of Pharmaceutical Products by Shanghai Transfusion to Shanghai Blood Centre	24,374,765.24	17,133,905.97	20,391,771.02

The annual cap proposed by the Company for the year ending 31 December 2009 is as follows:

Annual Cap

Transaction	Year ending 31 December 2009 (RMB)
	Cap
Supply of Pharmaceutical Products by Shanghai Transfusion to Shanghai Blood Centre	26,500,000

The Company has determined the annual cap for the year ending 31 December 2009 by reference to (i) the relevant historical figures for the three years ended 31 December 2006, 2007 and 2008, respectively; (ii) the estimated growth of the demand of pharmaceutical products by Shanghai Blood Centre; and (iii) the estimated growth of the pharmaceutical industry of the PRC in general.

Implementation Agreements

Shanghai Transfusion has entered into and will enter into, from time to time and as necessary, separate implementation agreements for each specific transaction contemplated under the 2008 Pharmaceutical Products Sales Agreement during the term thereof with Shanghai Blood Centre. Each implementation agreement will set out the specific products, price and other relevant specifications.

As the implementation agreements provide for products as contemplated by the 2008 Pharmaceutical Products Sales Agreement, as such, they do not constitute new categories of connected transactions. Any such implementation agreement will be within the ambit of the 2008 Pharmaceutical Products Sales Agreement and the relevant annual cap, and if exceeded, the Company will comply with the relevant Listing Rules accordingly.

Listing Rules Implications

Shanghai Transfusion is a subsidiary of the Company. Shanghai Blood Centre is a substantial shareholder of Shanghai Transfusion and is therefore a connected person of the Company, and the transaction under the 2008 Pharmaceutical Products Sales Agreement constitutes a continuing connected transaction of the Company under Chapter 14A of the Listing Rules.

As each of the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) in respect of the annual cap for the year ending 31 December 2009 is more than 0.1% but less than 2.5%, the transaction under the 2008 Pharmaceutical Products Sales Agreement for the year ending 31 December 2009 is only subject to the reporting and announcement

requirements under Rules 14A.45 to 14A.47 of the Listing Rules, and is exempt from the independent shareholders' approval requirement under Rule 14A.48 of the Listing Rules.

General

Appropriate disclosures of the continuing connected transaction under the 2008 Pharmaceutical Products Sales Agreement will be made in the annual report and accounts of the Company for the year ended 31 December 2008 and for the year ending 31 December 2009, respectively.

The Directors (including the independent non-executive Directors) are of the view that the terms of the continuing connected transaction under the 2008 Pharmaceutical Products Sales Agreement (i) have been negotiated on an arm's length basis; (ii) have been conducted and will be conducted on normal commercial terms, or on terms no less favourable than those available to independent third parties under prevailing local market conditions; (iii) are entered into in the ordinary and usual course of business of the Group; (iv) are fair and reasonable and in the interests of the Shareholders as a whole; and (v) that the annual cap for the year ending 31 December 2009 mentioned above are fair and reasonable.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiry, there is no other continuing transaction entered into between any member of the Group and Shanghai Blood Centre and its ultimate beneficial owner(s) or otherwise related, which would be, together with the continuing connected transaction under the 2008 Pharmaceutical Products Sales Agreement, aggregated under Rules 14A.27 of the Listing Rules.

REASONS FOR ENTERING INTO THE CONTINUING CONNECTED TRANSACTION

Shanghai Transfusion is principally engaged in the sales and distribution of pharmaceutical products. It supplies pharmaceutical products to Shanghai Blood Centre, being one of its customers, in its ordinary and usual course of business and on normal commercial terms.

GENERAL INFORMATION OF THE GROUP

The principal activities of the Group are: (i) pharmaceuticals; (ii) property development; (iii) steel; (iv) mining; (v) investments in retail business; and (vi) financial services and strategic investments.

GENERAL INFORMATION OF THE PARTIES TO THE CONTINUING CONNECTED TRANSACTION

Shanghai Transfusion

Shanghai Transfusion is a limited liability company incorporated under the laws of the PRC and is a subsidiary of the Company. It is principally engaged in the sales and distribution of pharmaceutical products.

Shanghai Blood Centre

Shanghai Blood Centre is an institutional unit (事業單位) established under the laws of the PRC and is a substantial shareholder of Shanghai Transfusion. It is a comprehensive medical and health institution mainly engaged in (i) blood collection and supply; (ii) scientific research in transfusion medicine; (iii) education and training; and (iv) blood products and transfusion appliance production. In 1988, World Health Organization designated Shanghai Blood Centre as a Collaborating Center for the Development and Research in the Services of Blood Transfusion.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions have the following meanings:

“Company”	Fosun International Limited (復星國際有限公司), a company incorporated under the laws of Hong Kong and whose shares are listed and traded on the main board of the Stock Exchange
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC”	the People’s Republic of China
"Prospectus"	the prospectus of the Company dated 29 June 2007

“RMB”	Renminbi yuan, the lawful currency of the PRC
“Shanghai Transfusion”	Shanghai Transfusion Technology Co., Ltd. (上海輸血技術有限公司), a limited liability company incorporated under the laws of the PRC and a subsidiary of the Company
“Shanghai Blood Centre”	Shanghai Blood Centre (上海市血液中心), an institutional unit (事業單位) established under the laws of the PRC
“Shareholders”	the shareholders of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“2006 Pharmaceutical Products Sales Agreement”	A pharmaceutical products sales agreement dated 22 August 2006 and entered into between Shanghai Transfusion and Shanghai Blood Centre in relation to the supply of pharmaceutical products by Shanghai Transfusion to Shanghai Blood Centre for a term of one year, namely, for the period from 22 August 2006 to 21 August 2007
“2008 Pharmaceutical Products Sales Agreement”	A pharmaceutical products sales agreement dated 12 August 2008 and entered into between Shanghai Transfusion and Shanghai Blood Centre in relation to the supply of pharmaceutical products by Shanghai Transfusion to Shanghai Blood Centre for a term of one year, namely, for the period from 12 August 2008 to 11 August 2009, which was extended to 31 December 2009 by a supplemental agreement dated 10 March 2009 and entered into by the parties

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

10 March 2009, Shanghai, the PRC

As at the date of this announcement, the Company’s executive directors are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.